Sonova (OTCMKTS:SONVY) Stock Gets Downgrade from UBS Group

Sonova (OTCMKTS:SONVY) was downgraded by research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

Several other equities analysts also recently weighed in on the company. The Goldman Sachs Group raised Sonova from a “hold” rating to a “buy” rating in a research report on Thursday, October 8th. Citigroup reissued a “sell” rating on shares of Sonova in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Sonova Stock Performance

SONVY opened at $68.42 on Monday. The stock’s 50-day moving average price is $61.51 and its 200 day moving average price is $53.34. Sonova has a 12-month low of $42.26 and a 12-month high of $69.66. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.75 and a quick ratio of 1.43.

About Sonova

Sonova Holding AG is a Switzerland-based hearing-care company that develops, manufactures and distributes solutions for people with hearing loss. Its portfolio includes hearing aids, cochlear implants, hearing implants, wireless communication products and related accessories and services.

The company markets products under several brands, including Phonak, Unitron and Advanced Bionics. Sonova also operates hearing-care businesses and retail networks that provide hearing assessments, device fitting, rehabilitation support and after-sales services.